Publication of Phase 1 study on clinicaltrials.gov

Ananda Pharma PLC

03 June 2025

 

 03 June 2025

ANANDA PHARMA PLC 

("Ananda" or the "Company") 

Publication of Ananda's Phase 1 study on clinicaltrials.gov

Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF), a UK-based biopharmaceutical company developing regulatory approved cannabidiol medicines to treat complex, chronic conditions is pleased to announce that the Company's Phase 1 pharmacokinetic (PK) study has been published on clinicaltrials.gov, with reference number NCT06854783.

MRX1 is Ananda's lead investigational cannabidiol (CBD) drug candidate in development for complex chronic inflammatory pain conditions. It is derived from high-purity, pharmaceutical-grade CBD, manufactured to EU GMP quality control standards to ensure consistency and stability.

The posting of the PK study on ClinicalTrials.gov is a required step in the lead-up to the commencement of clinical trials as it ensures transparency, ethical compliance, and alignment with international standards.

The Company intends to use the data generated from the trial to support its drug development pipeline, for future regulatory submissions in markets like the U.S and potentially to publish in high-impact medical journals.

Public registration of the trial in advance of commencement can also help raise awareness among potential participants by making trial information such as objectives, eligibility criteria, and contact details readily accessible.

Ananda's CEO, Melissa Sturgess commented: "The behind-the-scenes work is now starting to show in the public arena and demonstrates our commitment to the development of regulatory approved CBD medicines which are available to everyone who needs them, not just those who can afford them." 

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

To stay up to date with Ananda's news please follow our social media channels:  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor

-Ends-

ANANDA PHARMA PLC	[phone]
	[e-mail]
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE LLP
Corporate Broking	[phone]
Abigail Wayne	[e-mail]
Rob Rees	[e-mail]
Corporate Finance	[phone]
Richard Morrison
Josh Ray
VIRIDIAN CAPITAL ADVISORS (US) Scott Greiper	[phone] [e-mail]
YELLOW JERSEY PR Sarah MacLeod Charles Goodwin Zara McKinlay	[phone] [e-mail]

https://investors.anandapharma.co.uk/link/lejOgr

 

END